Avanos Medical (NYSE:AVNS) Releases FY 2024 Earnings Guidance

Avanos Medical (NYSE:AVNS) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance of 1.300-1.350 for the period, compared to the consensus EPS estimate of 1.390. The company issued revenue guidance of $683.0 million-$688.0 million, compared to the consensus revenue estimate of $695.2 million.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Avanos Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 26th.

Avanos Medical Stock Performance

AVNS opened at $18.71 on Friday. The company has a quick ratio of 1.49, a current ratio of 2.22 and a debt-to-equity ratio of 0.12. The firm has a market cap of $859.71 million, a PE ratio of 55.03 and a beta of 0.91. The business has a fifty day simple moving average of $23.13 and a 200-day simple moving average of $21.48. Avanos Medical has a fifty-two week low of $17.39 and a fifty-two week high of $25.36.

Avanos Medical (NYSE:AVNS) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.36 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.36. The business had revenue of $170.40 million during the quarter, compared to analyst estimates of $175.03 million. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%. As a group, equities analysts predict that Avanos Medical will post 1.33 EPS for the current fiscal year.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.